These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 11221780)

  • 1. Serotonin syndrome risk with antiobesity drug.
    Trakas K; Shear NH
    Can J Clin Pharmacol; 2000; 7(4):216. PubMed ID: 11221780
    [No Abstract]   [Full Text] [Related]  

  • 2. Sibutramine for obesity.
    Med Lett Drugs Ther; 1998 Mar; 40(1022):32. PubMed ID: 9529518
    [No Abstract]   [Full Text] [Related]  

  • 3. Weight-loss drug fattens heart risks.
    Consum Rep; 2003 Dec; 68(12):57. PubMed ID: 14680011
    [No Abstract]   [Full Text] [Related]  

  • 4. Psychosis with sibutramine.
    Rosenbohm A; Bux CJ; Connemann BJ
    J Clin Psychopharmacol; 2007 Jun; 27(3):315-7. PubMed ID: 17502790
    [No Abstract]   [Full Text] [Related]  

  • 5. Caution for new diet drug.
    Health News; 1998 Mar; 4(4):5. PubMed ID: 9553607
    [No Abstract]   [Full Text] [Related]  

  • 6. Weighing in on Meridia.
    Harv Womens Health Watch; 1998 Feb; 5(6):7. PubMed ID: 9600049
    [No Abstract]   [Full Text] [Related]  

  • 7. Is the new anti-obesity drug Meridia safer than fen-phen?
    Johns Hopkins Med Lett Health After 50; 1998 Apr; 10(2):8. PubMed ID: 9552806
    [No Abstract]   [Full Text] [Related]  

  • 8. [Questions surrounding sibutramine for obesity].
    Nau JY
    Rev Med Suisse; 2010 Jan; 6(231):76. PubMed ID: 20196440
    [No Abstract]   [Full Text] [Related]  

  • 9. Sibutramine (Meridia)--dental considerations for a new weight control drug.
    Wynn RL
    Gen Dent; 1998; 46(4):332-5. PubMed ID: 9758977
    [No Abstract]   [Full Text] [Related]  

  • 10. Sibutramine: an Australian analysis of reported adverse effects.
    Prescrire Int; 2007 Jun; 16(89):114. PubMed ID: 17590911
    [No Abstract]   [Full Text] [Related]  

  • 11. Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.
    Giese SY; Neborsky R
    Plast Reconstr Surg; 2001 Jan; 107(1):293-4. PubMed ID: 11176649
    [No Abstract]   [Full Text] [Related]  

  • 12. American Heart Association urges caution on new diet drug.
    Circulation; 1998 Feb; 97(7):B3. PubMed ID: 9495314
    [No Abstract]   [Full Text] [Related]  

  • 13. Withdrawal of sibutramine in Europe.
    Williams G
    BMJ; 2010 Feb; 340():c824. PubMed ID: 20144986
    [No Abstract]   [Full Text] [Related]  

  • 14. Diet drug helps keep weight off.
    Health News; 2001 Feb; 7(2):6. PubMed ID: 11232119
    [No Abstract]   [Full Text] [Related]  

  • 15. Sibutramine: balancing weight loss benefit and possible cardiovascular risk.
    de Simone G; D'Addeo G
    Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):337-41. PubMed ID: 18502626
    [No Abstract]   [Full Text] [Related]  

  • 16. [Observational study. Sibutramine in general practice].
    MMW Fortschr Med; 2001 Apr; 143(15):43. PubMed ID: 11349321
    [No Abstract]   [Full Text] [Related]  

  • 17. Obesity.
    Arterburn D
    Clin Evid; 2003 Dec; (10):676-89. PubMed ID: 15555115
    [No Abstract]   [Full Text] [Related]  

  • 18. Cardiovascular effects of sibutramine.
    Pisarik P
    Pediatrics; 2007 Oct; 120(4):930-1; author reply 931-2. PubMed ID: 17908786
    [No Abstract]   [Full Text] [Related]  

  • 19. [Sibutramin in obesity treatment (multicenter, open, prospective 12-month-long study)].
    Payer J; Hainer V; Ondrejka P; Kajtor Z
    Vnitr Lek; 2004 Nov; 50(11):825-9. PubMed ID: 15648961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The trial that killed a drug].
    Rössner S
    Lakartidningen; 2010 Sep 29-Oct 5; 107(39):2339. PubMed ID: 20976857
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.